# Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.

> **NCT03455387** · — · COMPLETED · sponsor: **Centre Hospitalier Metropole Savoie** · enrollment: 233 (actual)

## Conditions studied

- Pre-Eclampsia
- HELLP Syndrome
- Fetal Death
- Eclampsia
- Placental Abruption
- Fetal Growth Retardation, Antenatal

## Interventions

- **DIAGNOSTIC_TEST:** sampling of the serum marker sFlt1 and PlGF

## Key facts

- **NCT ID:** NCT03455387
- **Lead sponsor:** Centre Hospitalier Metropole Savoie
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-10
- **Primary completion:** 2019-12-20
- **Final completion:** 2019-12-31
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03455387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03455387, "Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03455387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*